Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Mostrar más
- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated...
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p <...
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.395 | 7.63964950712 | 18.26 | 19.86 | 17.96 | 823317 | 18.76983249 | CS |
| 4 | 0.175 | 0.898357289528 | 19.48 | 21.58 | 16.6 | 1297074 | 18.80896448 | CS |
| 12 | -4.805 | -19.6443172527 | 24.46 | 27.2 | 16.6 | 1452402 | 20.17856102 | CS |
| 26 | 1.745 | 9.74316024567 | 17.91 | 27.2 | 13.2 | 1397798 | 19.83332414 | CS |
| 52 | -0.475 | -2.35966219573 | 20.13 | 27.2 | 11.4 | 1175298 | 18.08752267 | CS |
| 156 | 1.225 | 6.6467715681 | 18.43 | 39 | 9.47 | 794507 | 19.84266021 | CS |
| 260 | -1.735 | -8.11126694717 | 21.39 | 39 | 9.47 | 615136 | 19.6772594 | CS |
Monksdream
4 meses hace
it_happens
5 meses hace
power11
5 meses hace
it_happens
5 meses hace
power11
5 meses hace
it_happens
5 meses hace
Monksdream
5 meses hace
Apprentice
3 años hace
Apprentice
3 años hace
crudeoil24
3 años hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
